Uterine Sarcoma Market Report 2026

Uterine Sarcoma Market Overview

• Uterine Sarcoma market size has reached to $2.8 billion in 2025 • Expected to grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: The Impact Of Personalized Medicine On The Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Uterine Sarcoma Market?

Uterine sarcoma is a rare and aggressive form of cancer that develops in the smooth muscle or connective tissue of the uterus, as opposed to the more common endometrial cancer, which originates in the lining of the uterus. This type of cancer is known for its potential to grow rapidly and spread to other areas of the body, making early diagnosis and intervention crucial for improving treatment outcomes. Uterine sarcomas are typically diagnosed through imaging tests, biopsy, and histological examination. The main types of uterine sarcoma are uterine leiomyosarcoma, undifferentiated sarcoma, endometrial stromal sarcoma, and other types. Uterine leiomyosarcoma is a rare and aggressive cancer originating from the smooth muscle of the uterus, characterized by high recurrence rates and poor prognosis. Diagnosis of uterine sarcoma involves various methods, such as tissue sampling and testing, imaging tests, and other diagnostic approaches. Treatment options include surgery, radiation therapy, hormone therapy, chemotherapy, and other modalities. The disease is managed by different end users, such as hospitals and clinics, academic institutions, research organizations, and other healthcare providers.

What Is The Uterine Sarcoma Market Growth Forecast?

The uterine sarcoma market size is expected to see strong growth in the next few years. It will grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing adoption of precision oncology treatments, rising investment in rare cancer research, expansion of targeted drug development, growing use of molecular diagnostics, increasing collaboration in oncology clinical trials. Major trends in the forecast period include increasing focus on early and accurate diagnosis, growing adoption of multimodal treatment approaches, rising use of advanced imaging and molecular testing, expansion of targeted and personalized therapies, enhanced integration of oncology care pathways.

Global Uterine Sarcoma Market Segmentation

1) By Type: Uterine Leiomyosarcoma, Undifferentiated Sarcoma, Endometrial Stromal Sarcoma, Other Types 2) By Diagnosis: Sampling And Testing, Imaging Tests, Other Diagnoses 3) By Treatment: Surgery, Radiation Therapy, Hormone Therapy, Chemotherapy, Other Treatments 4) By End User: Hospitals And Clinics, Academic Institutes, Research Organization, Other End Users Subsegments: 1) By Uterine Leiomyosarcoma: Primary Uterine Leiomyosarcoma, Metastatic Uterine Leiomyosarcoma 2) By Undifferentiated Sarcoma: High-Grade Undifferentiated Sarcoma, Low-Grade Undifferentiated Sarcoma 3) By Endometrial Stromal Sarcoma: Low-Grade Endometrial Stromal Sarcoma, High-Grade Endometrial Stromal Sarcoma, Endometrial Stromal Sarcoma With Sarcomatous Overgrowth 4) By Other Types: Mixed Epithelial And Mesenchymal Sarcoma, Malignant Mixed Mullerian Tumors

What Are The Drivers Of The Uterine Sarcoma Market?

The growth of personalized medicine is expected to propel the growth of the uterine sarcoma market going forward. Personalized medicine is a medical approach that tailors treatments and healthcare decisions based on individual genetic, environmental, and lifestyle factors. Personalized medicine is rising due to advancements in genomics, molecular profiling, and precision technologies, enabling tailored treatments that improve efficacy and reduce side effects. Uterine sarcoma contributes to personalized medicine by serving as a model for developing tailored approaches that leverage unique genetic and molecular insights to optimize diagnosis, treatment, and patient care. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the growth of personalized medicine is driving the growth of the uterine sarcoma industry. The rising healthcare expenditure is expected to propel the uterine sarcoma market going forward. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, infrastructure, and health-related programs. Rising healthcare expenditure is attributed to the aging population, increasing rates of chronic diseases, advancements in medical technology, and the growing demand for high-quality healthcare services. Uterine sarcoma benefits from healthcare expenditure by enabling increased investment in advanced diagnostic tools, innovative treatments, and research initiatives, leading to improved patient outcomes and enhanced care quality. For instance, in June 2025, according to the Centers for Medicare and Medicaid Services (CMS), a US-based federal government health data and statistical authority, US health care spending grew 7.5% in 2023, reaching $4.9 trillion or $14,570 per person, and accounted for 17.6% of the nation’s GDP. Therefore, the rising healthcare expenditure is driving the growth of the uterine sarcoma industry. The growing popularity of minimally invasive surgeries is expected to propel the growth of the uterine sarcoma market going forward. Minimally invasive surgeries refer to surgical procedures performed through small incisions using specialized instruments, often including laparoscopic or robotic-assisted techniques, which reduce recovery time and minimize tissue damage. The popularity of minimally invasive surgeries is rising because patients prefer procedures that cause less pain, shorten hospital stays, and allow them to return to normal activities more quickly. Minimally invasive surgeries support the treatment of uterine sarcoma by allowing surgeons to precisely remove tumors with smaller incisions, reducing trauma to surrounding tissues, speeding up patient recovery, and enabling earlier postoperative interventions. For instance, in January 2025, according to Intuitive Surgical, Inc., a US-based biotechnology company, in 2024, our customers utilized our products in nearly 2.7 million procedures, marking a 17% increase compared to 2023, bringing the total cumulative experience on da Vinci platforms to nearly 17 million procedures. During the year, we placed 1,430 da Vinci multiport systems, 271 Ion systems, and 96 da Vinci SP systems. Therefore, growing popularity of minimally invasive surgeries is driving the growth of the uterine sarcoma market.

Key Players In The Global Uterine Sarcoma Market

Major companies operating in the uterine sarcoma market are Merck And Co. Inc., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Incyte Corporation, Karyopharm Therapeutics Inc., Bayer AG, Nanobiotix, Iovance Biotherapeutics, Mirati Therapeutics, CytRx, Taiho Pharmaceuticals, Advenchen Laboratories, Philogen, Gradalis, Apexigen, Lytix Biopharma, Aadi Bioscience, AVEO Pharmaceuticals, VasGene Therapeutics, ImmunityBio

Regional Outlook

North America was the largest region in the uterine sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Uterine Sarcoma Market?

The uterine sarcoma market consists of sales of radiation therapy equipment, hormone therapy drugs, prosthetics and reconstructive surgery products, and immuno-oncology products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Uterine Sarcoma Market Report 2026?

The uterine sarcoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the uterine sarcoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.